BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER OCTOBER 2012)

Determination of Nevirapine in Human Plasma by HPTLC

Pranjali S. Ranaware1, Anita M. Ingle1, A. Ladke1, Ashwini R. Madgulkar2 & Mrinalini C. Damle3

Introduction:
 
Nevirapine 11-Cyclopropyl–5, 11–dihydro–4–methyl–6H-dipyrido [3,2–b:2′,3′-e]-[1,4]diazepin–6–one is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1infection and AIDS. A single dose of Nevirapine given to both mother and child reduced the rate of HIV transmission by almost 50%. Mechanism of action is as follows, NNRTIs exhibit a classical noncompetitive inhibition pattern with the enzyme reverse transcriptase. Nevirapine is readily absorbed after oral administration with a peak plasma concentration at 4 hr. Cmax for Nevirapine is 1-2 μg/ml. The concentration of the drug in the CNS is 45% of that in plasma. It crosses the placenta and has been detected in breast milk. Nevirapine undergoes extensive metabolism in the liver mainly by the cytochrome P450 isoenzymes of the CYP3A family. It is excreted via urine as the glucuronide conjugates of the hydroxylated metabolites. The drug is widely distributed in body tissues and the CNS1,2.

 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.